Cargando…
Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses
Certain RGD-binding integrins are required for cell adhesion, migration, and proliferation and are overexpressed in most tumors, making them attractive therapeutic targets. However, multiple integrin antagonist drug candidates have failed to show efficacy in cancer clinical trials. In this work, we...
Autores principales: | Kwan, Byron H., Zhu, Eric F., Tzeng, Alice, Sugito, Harun R., Eltahir, Ahmed A., Ma, Botong, Delaney, Mary K., Murphy, Patrick A., Kauke, Monique J., Angelini, Alessandro, Momin, Noor, Mehta, Naveen K., Maragh, Alecia M., Hynes, Richard O., Dranoff, Glenn, Cochran, Jennifer R., Wittrup, K. Dane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460993/ https://www.ncbi.nlm.nih.gov/pubmed/28473400 http://dx.doi.org/10.1084/jem.20160831 |
Ejemplares similares
-
Intratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice
por: Lutz, Emi A, et al.
Publicado: (2022) -
Chaperone proteins as single component reagents to assess antibody nonspecificity
por: Kelly, Ryan L., et al.
Publicado: (2017) -
Maximizing response to intratumoral immunotherapy in mice by tuning local retention
por: Momin, Noor, et al.
Publicado: (2022) -
Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice
por: Kang, Byong H., et al.
Publicado: (2021) -
An engineered protein antagonist of K-Ras/B-Raf interaction
por: Kauke, Monique J., et al.
Publicado: (2017)